Skip to main content

Advertisement

SpringerLink
Log in

Neurocognitive Impact of Antiretroviral Treatment: Thinking Long-Term

  • Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Combination antiretroviral therapy has significantly reduced morbidity and mortality with HIV infection. However, HIV-associated neurocognitive disorders persist at a relatively high prevalence rate despite successful systemic treatment. This paper reviews the current issues related to the neurocognitive impact of antiretroviral treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2009. This study indicates that the prevalence of cognitive complaints and HAND remains elevated in HIV-infected individuals who have been optimally treated and who have undetectable HIV-1 RNA concentrations.

  2. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol. 2004;10:350–7.

    Article  PubMed  Google Scholar 

  3. Schouten J, Cinque P, Gisslen M, et al. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS. 2011;25:000–16.

    Article  Google Scholar 

  4. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99.

    Article  PubMed  CAS  Google Scholar 

  5. Foley J, Ettenhofer M, Wright M, Hinkin C. Emerging issues in the neuropsychology of HIV infection. Curr HIV/AIDS Rep. 2008;5:204–11.

    Article  PubMed  Google Scholar 

  6. Dennis BC, Houff SA, Han DY, Schmitt FA. Development of neurocognitive disorders in HIV/AIDS. Neurobehav HIV Med. 2011;3:9–18.

    Google Scholar 

  7. Tozzi V, Balestra P, Galgani S, et al. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses. 2003;19:643–52.

    Article  PubMed  Google Scholar 

  8. Albert SM, Marder K, Doonief G, et al. Neurospychological impairment in early HIV infection. A risk factor for work disability. Arch Neurol. 1995;52:525–30.

    PubMed  CAS  Google Scholar 

  9. Heaton RK, Velin RA, McCutchan JA, et al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. Psychosom Med. 1994;56:8–17.

    PubMed  CAS  Google Scholar 

  10. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18 suppl 1:S19–25.

    PubMed  Google Scholar 

  11. Woods SP, Moran LM, Carey CL, et al. Prospective memory in HIV infection: is ‘remembering to remember’ a unique predictor of self-reported medication management? Arch Clin Neuropsychol. 2008;23:257–70.

    Article  PubMed  Google Scholar 

  12. Robertson K, Smurzynski M, Parsons T, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915–21.

    Article  PubMed  Google Scholar 

  13. • Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087–95. The CHARTER study presents baseline data on the frequency and associated features of HAND in 1555 HIV-infected subjects. Milder forms of neurocognitive impairment were found to be prevalent in this cohort, even among those receiving cART who had minimal comorbidities.

    Article  PubMed  Google Scholar 

  14. Heaton RK, Grant I, Butters N, et al. The HNRC 500: neuropsychology of HIV infection at different disease stages: HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:231–51.

    Article  PubMed  CAS  Google Scholar 

  15. White DA, Heaton RK, Monsch AU. Neuropsychological studies of asymptomatic human immunodeficiency virustype-1 infected individuals: The HNRC Group: HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:304–15.

    Article  PubMed  CAS  Google Scholar 

  16. Harrington PR, Schnell G, Letendre SL, et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS. 2009;23(8):907–15.

    Article  PubMed  Google Scholar 

  17. Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol. 2010;84(5):2395–407.

    Article  PubMed  CAS  Google Scholar 

  18. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66(9):1447–50.

    Article  PubMed  Google Scholar 

  19. Letendre S, McCutchan J, Childers M, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56:416–23.

    Article  PubMed  Google Scholar 

  20. Letendre S. Revised CNS penetration-effectiveness ranks. In 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2010.

  21. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357–65.

    Article  PubMed  Google Scholar 

  22. Brew B. HIV, the brain, children, HAART and ‘neuro-HAART’: a complex mix. AIDS. 2009;23:1909–10.

    Article  PubMed  Google Scholar 

  23. Patel K, Ming X, Williams PL, et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS. 2009;23:1893–901.

    Article  PubMed  Google Scholar 

  24. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74:1260–6.

    Article  PubMed  CAS  Google Scholar 

  25. • Liner J, Robertson K, Meeker R. Antiretroviral neurotoxicity. Poster presented at 39th Annual Neuroscience Meeting. Chicago, IL; 2009. This study demonstrates the potential neurotoxic mechanisms of ART on neuronal cultures. This study demonstrates the possibility of neurotoxic side effects of antiretrovirals on neuronal cultures.

  26. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359–66.

    Article  PubMed  Google Scholar 

  27. Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther. 2009;14:165–79.

    Article  PubMed  CAS  Google Scholar 

  28. Ragin A, Wu Y, Du H, et al. Injury to the brain is evident early in HIV infection. 18th Conference on Retroviruses and Opportunistic; February 27-March 2, 2011; Boston MA. Abstract 55LB.

  29. Valcour V, Sailasuta N, Chalermchai T, et al. HIV brain viral and inflammatory signature during acute infection. 18th Conference on Retroviruses and Opportunistic; February 27-March 2, 2011; Boston MA. Abstract 54.

  30. Wright EJ. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS. 2009;4:447–52.

    Article  PubMed  Google Scholar 

  31. Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007;69(24):2213–20.

    Article  PubMed  CAS  Google Scholar 

  32. Harezlak J, Buchthal S, Michael T, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25(5):625–33.

    Article  PubMed  CAS  Google Scholar 

  33. Smith G. Aging hearing: HIV over fifty, exploring the new threat. Senate Committee on Aging, 2006, Washington, DC.

  34. Ledergerber B. Epidemiology of HIV, including Response to ART, in Older Populations. 15th Conference on Retroviruses and Opportunistic Infections. 2-12-2008; Abstract 108 [on-line]. Available at http://www.retroconference.org/2008/Abstracts/33417.htm Accessed April 6, 2009.

  35. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS. 2008;22:1463–73.

    Article  Google Scholar 

  36. Mussini C, Manzardo C, Johnson M, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS. 2008;22:2461–9.

    Article  PubMed  Google Scholar 

  37. Onen NF, Overton ET, Seyfried W, et al. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials. 2010;11(2):100–9.

    Article  PubMed  Google Scholar 

  38. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–55.

    Article  PubMed  CAS  Google Scholar 

  39. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29–35.

    Article  PubMed  CAS  Google Scholar 

  40. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.

    Article  PubMed  CAS  Google Scholar 

  41. Samaras K, Wand H, Law M, et al. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. 2007;30(1):113–9.

    Article  PubMed  CAS  Google Scholar 

  42. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19(13):1375–83.

    Article  PubMed  CAS  Google Scholar 

  43. SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22(14):F17–24.

    Article  Google Scholar 

  44. • Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010;75(10):864–73. The SMART neurology substudy indicates an association between poorer neurocognitive performance and prior cardiovascular disease.

    Article  PubMed  CAS  Google Scholar 

  45. El Sadir WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.

    Article  Google Scholar 

  46. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73:1292–9.

    Article  PubMed  CAS  Google Scholar 

  47. Becker JT, Lopez OL, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS. 2004;18 Suppl 1:S11–8.

    PubMed  Google Scholar 

  48. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology. 2004;63(5):822–7.

    PubMed  CAS  Google Scholar 

  49. Malaspina L, Woods S, Moore D, Depp C, Letendre SL, Jeste D, et al. Successful cognitive aging in persons living with HIV infection. J Neurovirol. 2011;17:110–9.

    Article  PubMed  Google Scholar 

  50. Hardy DJ, Vance DE. The neuropsychology of HIV/AIDS in older adults. Neuroppsychol Rev. 2009;19:263–72.

    Article  Google Scholar 

  51. van Gorp WG, Miller EN, Marcotte TD, et al. The relationship between age and cognitive impairment in HIV-1 infection: findings from the Muliticenter AIDS Cohort Study and a clinical cohort. Neurology. 1994;44:929–35.

    PubMed  Google Scholar 

  52. Wilkie FL, Goodkin K, Khamis I, van Zuilen MH, Lee D, Lecusay R, Concha M, Symes S, Suarez P, Eisdorfer C. Cognitive functioning in younger and older HIV‐1‐infected adults. J Acquir Immune Defic Syndr. 2003 Jun 1;33 Suppl 2:S93–S105.

    Google Scholar 

  53. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197–207.

    PubMed  Google Scholar 

  54. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800–5.

    Article  PubMed  CAS  Google Scholar 

  55. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 2004;39:1507–13.

    Article  PubMed  Google Scholar 

  56. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;33:365–72.

    Article  PubMed  CAS  Google Scholar 

  57. Stebbing J, Waters L, Mandalia S, et al. Hepatitis C virus infection in HIV type 1–infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis. 2005;41:906–11.

    Article  PubMed  CAS  Google Scholar 

  58. Hinkin CH, Castellon SA, Levine AJ, et al. Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis. 2008;27:11–7.

    Article  PubMed  Google Scholar 

  59. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18:1169–77.

    Article  PubMed  Google Scholar 

  60. Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol. 2006;44:S25–7.

    Article  PubMed  Google Scholar 

  61. Sullivan PS, Hanson DL, Teshale EH, et al. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS. 2006;20:1171–9.

    Article  PubMed  Google Scholar 

  62. Zhang X, Xu J, Peng H, et al. HCV coinfection associated with slower disease progression in HIV-infected former plasma donors naive to ART. PLoS One. 2008;3:e3992.

    Article  PubMed  Google Scholar 

  63. Norman L, Kumar A. Neuropsychological complications of HIV disease and substances of abuse. Am J Infect Dis. 2006;2:115–24.

    Article  Google Scholar 

  64. Davies J, Everall IP, Weich S, et al. HIV-associated brain pathology in the United Kingdom: an epidemiological study. AIDS. 1997;11:1145–50.

    Article  PubMed  CAS  Google Scholar 

  65. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR. Acceleration of HIV dementia with methamphetamine and cocaine. J Neurovirol. 2001;7:66–71.

    Article  PubMed  CAS  Google Scholar 

  66. Ferris MJ, Mactutus CF, Booze RM. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev. 2008;32:883–909.

    Article  PubMed  CAS  Google Scholar 

  67. Burdo TH, Katner SN, Taffe MA, Fox HS. Neuroimmunity, drugs of abuse, and neuroAIDS. J Neuroimmune Pharmacol. 2006;1:41–9.

    Article  PubMed  Google Scholar 

  68. Simon SL, Domier CP, Sim T, et al. Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis. 2002;21(1):61–74.

    Article  PubMed  Google Scholar 

  69. Gaskill P, Calderon T, Luers A, et al. Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am J Pathol. 2009;175:1148–59.

    Article  PubMed  CAS  Google Scholar 

  70. Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. Am J Psychiatry. 2004;161(2):249–54.

    Article  PubMed  Google Scholar 

  71. Carrieri MP, Moatti JP, Vlahov D, et al. Access to antiretroviral treatment among French HIV infected injection users: the influence of continued drug use. J Epidemiol Community Health. 1999;53:4–8.

    Article  PubMed  CAS  Google Scholar 

  72. Gibson DR, McCusker J, Chesney M. Effectiveness of psychosocial interventions in preventing HIV risk behavior in injecting drug users. AIDS. 1998;12:919–29.

    Article  PubMed  CAS  Google Scholar 

  73. McCusker J, Westenhouse J, Stoddard AM, et al. Use of drugs and alcohol by homosexually active men in relation to sexual practices. J Acquir Immune Defic Syndr. 1990;3:729–36.

    PubMed  CAS  Google Scholar 

  74. Applebaum AJ, Reilly LC, Gonzalez JS, et al. The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care STDS. 2009;23(6):455–62.

    Article  PubMed  Google Scholar 

  75. Lucas G. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2010;88:948–52.

    Article  PubMed  Google Scholar 

Download references

Disclosure

M. E. McPhail: none; K. R. Robertson: honoraria from Abbott, GlaxoSmithKline, and Tibotec.

Author information

Authors and Affiliations

  1. School of Medicine, University of North Carolina at Chapel Hill, 2127 Physicians Office Building, 170 Manning Drive, Chapel Hill, NC, 27599, USA

    Megan E. McPhail & Kevin R. Robertson

Authors
  1. Megan E. McPhail
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin R. Robertson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin R. Robertson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McPhail, M.E., Robertson, K.R. Neurocognitive Impact of Antiretroviral Treatment: Thinking Long-Term. Curr HIV/AIDS Rep 8, 249–256 (2011). https://doi.org/10.1007/s11904-011-0091-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-011-0091-7

Keywords

Search

Navigation